Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees

About this update from Pacira Biosciences, Inc.

ISS Concludes "There is a Compelling Reason to Support all Management Nominees" and Notes "the Dissident Has Not Presented a Compelling Case for Change"BRISBANE, Calif., June 1, 2026 /PRNewswire/ -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that leading independent proxy advisory firm Institutional Shareholder Services, Inc. ("ISS") has recommended that Pacira stockholders vote "FOR" each of Pacira's three director nominees – Christopher Christie, Samit Hirawat, MD and Thomas Wiggans – and "AGAINST" all three of DOMA Perpetual Capital Management LLC's ("DOMA Perpetual" or "DOMA")1 nominees on the BLUE proxy card ahead of the Company's 2026 Annual Meeting of Stockholders (the "Annual Meeting") on June 9, 2026. In its report, ISS noted that Pacira's performance measurably improved following the launch of its 5x30 strategy for stockholder value creation, and that the Company is guided by a refreshed and proactive board comprised of highly qualified directors with relevant industry and corporate governance experience. In contrast, ISS emphasized that DOMA has pursued an unsubstantiated and unconvincing campaign built around director nominees that lack public company board experience.ISS also noted the following in its report:2Regarding the Pacira Board's Track Record and Composition:"[T]he board's approach to refreshment, overseeing management, and guiding strategy appear to be more relevant considerations at this specific meeting. The board has been proactive in these areas, and the dissident has failed to establish that decisions have not aligned with the best interests of shareholders.""[I]t also appears that the board detected challenges before they directly impacted performance, and made proactive changes that positioned PCRX to pursue the revised strategy on an accelerated basis.""The board has taken steps to strengthen aspects of corporate governance. Notably, the board separated the roles of CEO and chair upon appointing Frank Lee CEO in January 2024 ... The board deserves credit for recognizing and addressing this issue.""[S]even out of 10 directors were either appointed or have been proposed for election since October 2023 … Collectively, these seven directors have experi...

View stock analysis, news, and events for Pacira Biosciences, Inc.